Griffiths CEM, Armstrong AW, Gudjonsson JE, et al. Psoriasis. Lancet. 2021;397(10281):1301–15. https://doi.org/10.1016/s0140-6736(20)32549-6.

Article  CAS  PubMed  Google Scholar 

Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–72. https://doi.org/10.1016/j.jaad.2018.11.057.

Article  PubMed  Google Scholar 

Nast A, Smith C, Spuls PI, et al. EuroGuiDerm Guideline on the systemic treatment of psoriasis vulgaris. Part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol. 2020;34(11):2461–98. https://doi.org/10.1111/jdv.16915.

Article  CAS  PubMed  Google Scholar 

EMA. Bimzelx (bimekizumab). 2021. https://www.ema.europa.eu/en/documents/overview/bimzelx-epar-medicine-overview_en.pdf. Accessed 9 Apr 2024.

Kennedy-Martin T, Curtis S, Faries D, et al. A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results. Trials. 2015;3(16):495. https://doi.org/10.1186/s13063-015-1023-4.

Article  Google Scholar 

Yiu ZZN, Mason KJ, Barker J, et al. A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real-world populations in psoriasis. Br J Dermatol. 2019;181(6):1265–71. https://doi.org/10.1111/bjd.17849.

Article  CAS  PubMed  PubMed Central  Google Scholar 

van den Reek J, Kievit W, Gniadecki R, et al. Drug survival studies in dermatology: principles, purposes, and pitfalls. J Invest Dermatol. 2015;135(7):1–5. https://doi.org/10.1038/jid.2015.171.

Article  CAS  PubMed  Google Scholar 

Lin PT, Wang SH, Chi CC. Drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence. Sci Rep. 2018;8(1):16068. https://doi.org/10.1038/s41598-018-34293-y.

Article  CAS  PubMed  PubMed Central  Google Scholar 

No DJ, Inkeles MS, Amin M, et al. Drug survival of biologic treatments in psoriasis: a systematic review. J Dermatolog Treat. 2018;29(5):460–6. https://doi.org/10.1080/09546634.2017.1398393.

Article  CAS  PubMed  Google Scholar 

Mourad AI, Gniadecki R. Biologic drug survival in psoriasis: a systematic review & comparative meta-analysis. Front Med (Lausanne). 2020;7: 625755. https://doi.org/10.3389/fmed.2020.625755.

Article  PubMed  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;29(372): n71. https://doi.org/10.1136/bmj.n71.

Article  Google Scholar 

Page MJ, Moher D, Bossuyt PM, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372: n160. https://doi.org/10.1136/bmj.n160.

Article  PubMed  PubMed Central  Google Scholar 

Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283(15):2008–12. https://doi.org/10.1001/jama.283.15.2008.

Article  CAS  PubMed  Google Scholar 

Ouzzani M, Hammady H, Fedorowicz Z, et al. Rayyan: a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210. https://doi.org/10.1186/s13643-016-0384-4.

Article  PubMed  PubMed Central  Google Scholar 

Hayden JA, van der Windt DA, Cartwright JL, et al. Assessing bias in studies of prognostic factors. Ann Intern Med. 2013;158(4):280–6. https://doi.org/10.7326/0003-4819-158-4-201302190-00009.

Article  PubMed  Google Scholar 

Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;12(355): i4919. https://doi.org/10.1136/bmj.i4919.

Article  Google Scholar 

Combescure C, Foucher Y, Jackson D. Meta-analysis of single-arm survival studies: a distribution-free approach for estimating summary survival curves with random effects. Stat Med. 2014;33(15):2521–37. https://doi.org/10.1002/sim.6111.

Article  PubMed  Google Scholar 

Jackson D, White IR, Riley RD. Quantifying the impact of between-study heterogeneity in multivariate meta-analyses. Stat Med. 2012;31(29):3805–20. https://doi.org/10.1002/sim.5453.

Article  PubMed  PubMed Central  Google Scholar 

Williamson PR, Smith CT, Hutton JL, et al. Aggregate data meta-analysis with time-to-event outcomes. Stat Med. 2002;21(22):3337–51. https://doi.org/10.1002/sim.1303.

Article  PubMed  Google Scholar 

Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;7(8):16. https://doi.org/10.1186/1745-6215-8-16.

Article  Google Scholar 

Mourad A, Straube S, Armijo-Olivo S, et al. Factors predicting persistence of biologic drugs in psoriasis: a systematic review and meta-analysis. Br J Dermatol. 2019;181(3):450–8. https://doi.org/10.1111/bjd.17738.

Article  CAS  PubMed  Google Scholar 

Klein JP, Logan B, Harhoff M, et al. Analyzing survival curves at a fixed point in time. Stat Med. 2007;26(24):4505–19. https://doi.org/10.1002/sim.2864.

Article  PubMed  Google Scholar 

Caldarola G, Chiricozzi A, Megna M, et al. Real-life experience with ixekizumab in plaque psoriasis: a multi-center, retrospective, 3-year study. Expert Opin Biol Ther. 2023;23(4):365–70. https://doi.org/10.1080/14712598.2023.2193288.

Article  CAS  PubMed  Google Scholar 

Caldarola G, Mariani M, Pirro F, et al. Comparison of short- and long-term effectiveness of ixekizumab and secukinumab in real-world practice. Expert Opin Biol Ther. 2021;21(2):279–86. https://doi.org/10.1080/14712598.2021.1849133.

Article  CAS  PubMed  Google Scholar 

Costa De Lima E, Gollo Mazzotti N, Palominos P, et al. Drug survival of biological therapy in south brazilian psoriasis patients. J Dermatol Nurses Assoc. 2020;12(2).

Daudén E, de Lima GPG, Armesto S, et al. Multicenter retrospective study of secukinumab drug survival in psoriasis patients in a daily practice setting: a long-term experience in Spain. Dermatol Ther (Heidelb). 2021;11(6):2207–15. https://doi.org/10.1007/s13555-021-00606-9.

Article  PubMed  PubMed Central  Google Scholar 

Elgaard CDB, Iversen L, Hjuler KF. Guselkumab, tildrakizumab, and risankizumab in a real-world setting: drug survival and effectiveness in the treatment of psoriasis and psoriatic arthritis. J Dermatolog Treat. 2023;34(1):2133531. https://doi.org/10.1080/09546634.2022.2133531.

Article  CAS  PubMed  Google Scholar 

Fitzgerald T, Zhdanava M, Pilon D, et al. Long-term psoriasis control with guselkumab, adalimumab, secukinumab, or ixekizumab in the USA. Dermatol Ther (Heidelb). 2023;13(4):1053–68. https://doi.org/10.1007/s13555-023-00910-6.

Article  PubMed  PubMed Central  Google Scholar 

Galluzzo M, Marcelli L, Vellucci L, et al. Guselkumab for treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and drug-survival for up to 148 weeks. Expert Opin Biol Ther. 2023;23(4):371–81. https://doi.org/10.1080/14712598.2023.2194485.

Article  CAS  PubMed  Google Scholar 

Gerdes S, Asadullah K, Hoffmann M, et al. Real-world evidence from the non-interventional, prospective, German multicentre PERSIST study of patients with psoriasis after 1 year of treatment with guselkumab. J Eur Acad Dermatol Venereol. 2022;36(9):1568–77. https://doi.org/10.1111/jdv.18218.

Article  CAS  PubMed  Google Scholar 

Gulliver W, Gooderham MJ, Zhu B, et al. Treatment persistence of ixekizumab in adults with moderate-to-severe plaque psoriasis participating in the Canadian Patient Support Program. Dermatol Ther (Heidelb). 2023;13(1):235–44. https://doi.org/10.1007/s13555-022-00853-4.

Article  PubMed  Google Scholar 

Gulliver W, Penney M, Power R, et al. Moderate-to-severe plaque psoriasis patients treated with ixekizumab: early real-world outcomes and adverse events. J Dermatol Treat. 2022;33(1):354–60. https://doi.org/10.1080/09546634.2020.1755009.

Article  CAS  Google Scholar 

Gooderham MJ, Lynde C, Turchin I, et al. Real-world, long-term treatment patterns of commonly used biologics in Canadian patients with moderate-to-severe chronic plaque psoriasis. J Dermatol. 2022;49(1):95–105. https://doi.org/10.1111/1346-8138.16214.

Article  CAS  PubMed  Google Scholar 

Goon PKC, Banfield CC, Bello O, et al. Real-world NHS drug survival and efficacy data for Secukinumab in chronic plaque psoriasis. J Eur Acad Dermatol Venereol. 2020;34(11):e716–8. https://doi.org/10.1111/jdv.16538.

Article  CAS  PubMed  Google Scholar 

Herranz-Pinto P, Alonso-Pacheco ML, Feltes-Ochoa R, et al. Real-world performance of a new strategy for off-label use of guselkumab in moderate to severe psoriasis: super-responder patients as the epitome of efficacy and optimisation. Clin Drug Investig. 2023;43(7):517–27. https://doi.org/10.1007/s40261-023-01280-9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huang YH, Tang CH, Goh CH, et al. Persistence and adherence to biologics in patients with psoriasis in Taiwan: a new biologics user cohort study. Front Pharmacol. 2022;13: 880985. https://doi.org/10.3389/fphar.2022.880985.

Article  CAS  PubMed  PubMed Central